Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACVRL1 | P37023 | 4/20 | 0.46 |
| ▸ | CSNK2A2 | P19784 | 6/20 | 0.40 |
| ▸ | CSNK2A1 | P68400 | 6/20 | 0.40 |
| ▸ | TYRO3 | Q06418 | 3/20 | 0.39 |
| ▸ | AXL | P30530 | 2/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.38 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.36 |
| ▸ | POLRMT | O00411 | 1/20 | 0.35 |
| ▸ | CDC7 | O00311 | 1/20 | 0.35 |
| ▸ | PLK4 | O00444 | 1/20 | 0.35 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.35 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.35 |
| ▸ | INSR | P06213 | 1/20 | 0.35 |
| ▸ | LCK | P06239 | 1/20 | 0.35 |
| ▸ | FYN | P06241 | 1/20 | 0.35 |
| ▸ | CDK1 | P06493 | 1/20 | 0.35 |
| ▸ | RET | P07949 | 1/20 | 0.35 |
| ▸ | ROS1 | P08922 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16011257 | 1.00 | ACVRL1 (0.46) | ACVRL1CSNK2A2CSNK2A1TYRO3AXL | |
| SCHEMBL31391115 | 0.92 | MAP4K4 (0.43) | ACVRL1MAP4K4DOT1LPOLRMT | |
| SCHEMBL27315074 | 0.86 | MAP4K4 (0.41) | ACVRL1MAP4K4KDR | |
| SCHEMBL19429619 | 0.85 | CSNK2A2 (0.38) | ACVRL1CSNK2A2CSNK2A1MAP4K4DOT1L | |
| SCHEMBL19377633 | 0.84 | AXL (0.39) | ACVRL1TYRO3AXLMAP4K4DOT1L | |
| SCHEMBL5128661 | 0.82 | CSNK2A2 (0.40) | ACVRL1CSNK2A2CSNK2A1TYRO3AXL | |
| SCHEMBL22627061 | 0.82 | ACVRL1 (0.51) | ACVRL1TYRO3MAP4K4 | |
| SCHEMBL19377694 | 0.82 | PIK3CD (0.42) | CSNK2A2CSNK2A1TYRO3AXLMAP4K4 | |
| SCHEMBL19377637 | 0.82 | EGLN2 (0.40) | ACVRL1TYRO3MAP4K4DOT1LJAK2 | |
| SCHEMBL19377763 | 0.81 | TYRO3 (0.45) | CSNK2A2CSNK2A1TYRO3MAP4K4DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12534479-B2 | Triazine compound and composition and use thereof | FINDCURE BIOSCIENCES (ZHONGSHAN) CO., LTD. (CN) | 2026-01-27 | — | — | US | disclosed |
| US-20230279024-A1 | TRIAZINE COMPOUND AND COMPOSITION AND USE THEREOF | BEIJING FINDCURE BIOSCIENCES, LTD. (CN) | 2023-09-07 | — | — | US | disclosed |
| EP-4180433-A1 | TRIAZINE COMPOUND AND COMPOSITION AND USE THEREOF | Beijing Findcure Biosciences, Ltd. (CN) | 2023-05-17 | — | — | EP | disclosed |
| EP-2726482-B1 | HYDROXYMETHYLARYL-SUBSTITUTED PYRROLOTRIAZINES AS ALK1 INHIBITORS | BAYER IP GMBH (DE) | 2016-07-20 | — | — | EP | disclosed |
| US-9040691-B2 | Hydroxymethylaryl-substituted pyrrolotriazines as ALK1 inhibitors | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-05-26 | — | — | US | disclosed |
| US-9040691-B2 | Hydroxymethylaryl-substituted pyrrolotriazines as ALK1 inhibitors | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-05-26 | — | — | US | disclosed |
| US-9040691-B2 | Hydroxymethylaryl-substituted pyrrolotriazines as ALK1 inhibitors | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-05-26 | — | — | US | disclosed |
| US-20140256718-A1 | HYDROXYMETHYLARYL-SUBSTITUTED PYRROLOTRIAZINES AS ALK1 INHIBITORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-09-11 | — | — | US | disclosed |
| US-20140256718-A1 | HYDROXYMETHYLARYL-SUBSTITUTED PYRROLOTRIAZINES AS ALK1 INHIBITORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-09-11 | — | — | US | disclosed |
| US-20140256718-A1 | HYDROXYMETHYLARYL-SUBSTITUTED PYRROLOTRIAZINES AS ALK1 INHIBITORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12534479-B2 | Triazine compound and composition and use thereof | JAK1, CCR1, PEAK1 | ACVRL1 1619/4885CSNK2A2 54/4885CSNK2A1 19/4885 |
| US-20140256718-A1 | HYDROXYMETHYLARYL-SUBSTITUTED PYRROLOTRIAZINES AS ALK1 INHIBITORS | ALK, FLT1, ACVR1 | ACVRL1 4/4885CSNK2A2 3473/4885CSNK2A1 2871/4885 |
| US-20230279024-A1 | TRIAZINE COMPOUND AND COMPOSITION AND USE THEREOF | JAK1, MAP3K5, MAP3K15 | ACVRL1 1152/4885CSNK2A2 134/4885CSNK2A1 88/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.